Law360, New York (October 29, 2009) -- AstraZeneca Pharmaceuticals LP has agreed to pay $520 million to settle an investigation by the U.S. Attorney's Office for the Eastern District of Pennsylvania into sales and marketing practices for the company's antipsychotic drug Seroquel.
The company disclosed the settlement in its third-quarter results released on Thursday. According to the report, AstraZeneca reached an agreement in principle with the U.S. attorney to resolve the investigation...


